Palvella Therapeutics PVLA Operating lease liabilities

Operating lease liabilities at other companies

PrecigenPGEN

——

Kodiak Sciences IncKOD

——

BridgeBio PharmaBBIO

——

Arrowhead ResearchARWR

——

Roivant SciencesROIV

——

Viking TherapeuticsVKTX

——

Other financials

Income statement

See full

Revenue$53.0K-97.3%

Operating income-$14.9M-88.7%

Net income-$15.8M-92.6%

EPS (diluted)-$1.20-62.2%

Balance sheet

See full

Cash & equivalents$206.4M+173%

Total debt$584.0K—

Total equity$232.3M+318%

Total assets$263.8M+232%

Cash flow

See full

Operating cash flow-$10.9M-60.5%

CapEx--100%

Free cash flow-$2.7M+72.0%

Valuation

See full

Market cap$1.7B+468%

Enterprise value$1.5B—

P/S41.6×—

Profitability

See full

Operating margin-183.2%-13.5pp

Net margin71.7%+40.4pp

FCF margin-99.8%-34.2pp

Returns & leverage

See full

Return on equity-34.2%—

Debt / equity0×—

Current ratio28.9×+20.0×

Where this comes from

Reported directly by Palvella Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Palvella Therapeutics's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Palvella Therapeutics's operating lease liabilities?: Palvella Therapeutics (PVLA) reported operating lease liabilities of -$49K in Q1 2026.